Skip to main content

Advertisement

SpringerLink
Log in

Low responsiveness to thienopyridine in hemodialysis patients

  • Original Article
  • Published:
Cardiovascular Intervention and Therapeutics Aims and scope Submit manuscript

Abstract

We sought to evaluate whether thienopyridine low responsiveness, a predictor of stent thrombosis, is found in hemodialysis patients. We measured platelet aggregation at the site of implantation of drug-eluting stents in 333 patients with angina pectoris undergoing dual anti-platelet therapy. Thirty-one patients were on hemodialysis (HD group), and 302 were not (N-HD group). We used a novel whole-blood aggregometer. The aggregometer used the screen filtration method, with adenosine diphosphate as an agonist. The concentration of agonist required to induce 50% of the maximum pressure rate was calculated and indicated as the platelet aggregatory threshold index (PATI). Low responsiveness for thienopyridine was defined if the PATI levels were <4 μmol/l. PATI levels (μmol/l) were significantly lower in the HD group than in the N-HD group (6.8 ± 4.8 vs. 9.1 ± 5.4, P = 0.023), and the rate of low responsiveness for thienopyridine was significantly higher in the HD group than in the N-HD group (45.7 vs. 26.8%, P = 0.019). Non-fatal myocardial infarction and stent thrombosis occurred in three of the HD group and in nine of the N-HD group (P = 0.122). Late stent thrombosis occurred at a significantly higher rate in the HD group than in the N-HD group (P = 0.002). The rate of target lesion revascularization was significantly higher in the HD group than in the N-HD group (38 vs. 11.8%, P = 0.0001). In conclusion, low responsiveness to thienopyridine, as an indicator of platelet reactivity, is found more frequently in hemodialysis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Steinhubl SR, Berger PB, Tift Mann J III, Fry ETA, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2.

    Article  CAS  PubMed  Google Scholar 

  2. Bhatt DL, Bertrand ME, Beger PB, L’Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparison of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39:9–14.

    Article  CAS  PubMed  Google Scholar 

  3. Park D-W, Park S-W, Park KH, Lee BK, Kim YH, Lee CW, et al. Frequency and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow up. Am J Cardiol. 2006;98:352–6.

    Article  PubMed  Google Scholar 

  4. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stent. JAMA. 2005;293:2126–30.

    Article  CAS  PubMed  Google Scholar 

  5. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. J Am Coll Cardiol. 2005;46:1827–32.

    Article  CAS  PubMed  Google Scholar 

  6. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Pamiccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312–7.

    Article  CAS  PubMed  Google Scholar 

  7. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008;52:734–9.

    Article  CAS  PubMed  Google Scholar 

  8. Schwarz U, Buzekko M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–23.

    Article  CAS  PubMed  Google Scholar 

  9. Ishio N, Kobayashi Y, Takebayashi H, Ijima Y, Kanda J, Nakayama T, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dailysis patients. Circ J. 2007;71:1525–9.

    Article  PubMed  Google Scholar 

  10. Okada T, Hayashi Y, Toyofuku M, Imazu M, Otsuka M, Sakuma T, et al. One-year clinical outcomes of dialysis patients after implantation with sirolimus-eluting stents. Circ J. 2008;72:1430–5.

    Article  PubMed  Google Scholar 

  11. de la Torre-Harnandez JM, Alfonso F, Hernandez F, Elizaga J, Sanmartin M, Pinar E, et al. Drug-eluting stent thrombosis results from the multicenter Spanish registory ESTROFA. J Am Coll Cardiol. 1008;51:986–90.

    Google Scholar 

  12. Ozeki Y, Sudo T, Toga K, Nagamura Y, Ito H, Ogawa T, et al. Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method. Thromb Res. 2001;101:65–72.

    Article  CAS  PubMed  Google Scholar 

  13. Sudo T, Ito H, Ozeki Y, Kimur Y. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol. 2001;133:1396–404.

    Article  CAS  PubMed  Google Scholar 

  14. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenisity in mice. J Biol Chem. 2004;279:35798–802.

    Article  CAS  PubMed  Google Scholar 

  15. Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawano M, Morimoto T, et al. Action of aspirin on whole blood-aggregation elevated by screen filtration pressure method. Circ J. 2008;72:420–6.

    Article  CAS  PubMed  Google Scholar 

  16. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post stenting: results of the prepare post-stenting study. J Am Coll Cardiol. 2005;46:1820–6.

    Article  CAS  PubMed  Google Scholar 

  17. Price MJ, Endemann S, Gollapudi RR, Valenica R, Stinis CT, Levisary JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992–1000.

    Google Scholar 

  18. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12 month follow-up. Circulation. 2009;119:237–42.

    Article  PubMed  Google Scholar 

  19. Campo G, Valgimigi M, Gemmati D, Percoco G, Catozzi L, Frangione A, et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? J Am Coll Cardiol. 2007;50:1132–7.

    Article  CAS  PubMed  Google Scholar 

  20. Yip HK, Wu CJ, Hang CL, Chang HW, Hung WC, Yeh KH, et al. Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation. Circ J. 2005;69:1208–11.

    Article  CAS  PubMed  Google Scholar 

  21. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation. 2002;106:2207–11.

    Article  PubMed  Google Scholar 

  22. Ashman H, Macey MG, Fan SL, Azam U, Yaqoob MM. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrol Dial Transplant. 2003;18:2088–96.

    Article  CAS  PubMed  Google Scholar 

  23. Kaufman JS, Fiore L, Hasbargen JA, O’Connor TZ, Perdriset G. A Phamacodynamic study of clopidogrel in chronic hemodialysis patients. J Thrombosis and Thrombolysis. 2000;10:127–31.

    Article  CAS  Google Scholar 

  24. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol. 2006;48:421–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Kumamoto Central Hospital, 1-5-1 Tainoshima, Kumamoto, 862-0965, Japan

    Shuichi Oshima, Katsuo Noda, Hironobu Fukushima, Shinichi Nakamura, Makoto Shono, Fumihito Kugimiya & Kenichiro Higa

Authors
  1. Shuichi Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsuo Noda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hironobu Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Shono
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fumihito Kugimiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenichiro Higa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichi Oshima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oshima, S., Noda, K., Fukushima, H. et al. Low responsiveness to thienopyridine in hemodialysis patients. Cardiovasc Interv and Ther 25, 18–23 (2010). https://doi.org/10.1007/s12928-009-0002-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12928-009-0002-7

Keywords

Search

Navigation